Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2020

Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

Carolina Alves-Costa Silva
  • Fonction : Auteur
Yacine Haddad
  • Fonction : Auteur

Résumé

Accumulating evidence from preclinical studies and human trials demonstrated the crucial role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade. In summary, it appears that a diverse intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota composition that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. In this review, we explore preclinical and translational studies highlighting how eubiotic and dysbiotic microbiota composition can affect progression-free survival in cancer patients.

Dates et versions

hal-03681591 , version 1 (30-05-2022)

Identifiants

Citer

Romain Daillère, Bertrand Routy, Anne-Gaëlle Goubet, Alexandria Cogdill, Gladys Ferrere, et al.. Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. OncoImmunology, 2020, 9 (1), ⟨10.1080/2162402x.2020.1794423⟩. ⟨hal-03681591⟩
50 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More